Closo-carboranyl- and metallacarboranyl [1,2,3]triazolyl-decorated lapatinib-scaffold for cancer therapy combining tyrosine kinase inhibition and boron neutron capture therapy

One of the driving forces of carcinogenesis in humans is the aberrant activation of receptors; consequently, one of the most promising mechanisms for cancer treatment is receptor inhibition by chemotherapy. Although a variety of cancers are initially susceptible to chemotherapy, they eventually deve...

Descripció completa

Dades bibliogràfiques

Autor principal:	Couto, Marcos (author)
Altres autors:	Alamón, Catalina (author), García Melián, María Fernanda (author), Kovacs, Mariángeles (author), Trias, Emiliano (author), Nievas, S. (author), Pozzi, E. (author), Curotto, P. (author), Thorp, S. (author), Dagrosa, M. A. (author), Teixidor, Francesc (author), Viñas, Clara (author), Cerecetto, Hugo (author)
Format:	article
Idioma:	anglès
Publicat:	2020
Matèries:	Tyrosine kinase inhibitors Lapatinib [1,2,3]triazolyl linker Boron clusters In vitro BNCT effect
Accés en línia:	https://hdl.handle.net/20.500.12008/32294
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!